Skip to main content
SpringerLink
Log in

Treatment of psoriasis vulgaris with guselkumab in a patient with non-small cell lung cancer

  • Correspondence
  • Published:
European Journal of Dermatology

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Paul CF, Ho VC, McGeown C, et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5-year cohort study. J Invest Dermatol 2003; 120: 211–6.

    Article  CAS  Google Scholar 

  2. Fiorentino D, Ho V, Lebwohl MG, et al. Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry. J Am Acad Dermatol 2017; 77: 845–54.e5.

    Article  Google Scholar 

  3. Chiesa Fuxench ZC, Shin DB, Ogdie Beatty A, Gelfand JM. The risk of cancer in patients with psoriasis: a population-based cohort study in the health improvement network. JAMA Dermatol 2016; 152: 282–90.

    Article  Google Scholar 

  4. Saeki H, Terui T, Morita A, et al. Japanese guidance for use of biologics for psoriasis (the 2019 version). J Dermatol 2020; 47: 201–22.

    Article  Google Scholar 

  5. Langowski JL, Zhang X, Wu L, et al. IL-23 promotes tumour incidence and growth. Nature 2006; 442: 461–5.

    Article  CAS  Google Scholar 

  6. Lu X. Impact of IL-12 in cancer. Curr Cancer Drug Targets 2017; 17: 682–97.

    Article  CAS  Google Scholar 

  7. Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nabpaclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a Phase III trial. J Clin Oncol 2012; 30: 2055–62.

    Article  CAS  Google Scholar 

  8. Vaengebjerg S, Skov L, Egeberg A, et al. Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. JAMA Dermatol 2020. doi: https://doi.org/10.1001/jamadermatol.2020.0024.

  9. Reich K, Griffiths CEM, Gordon KB, et al. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials. J Am Acad Dermatol 2020; 82: 936–45.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Jichi Medical University, Shimotsuke, Japan

    Koji Kamiya & Mamitaro Ohtsuki

  2. Division of Pulmonary Medicine, Department of Medicine, Jichi Medical University, Shimotsuke, Japan

    Hiroyoshi Yamauchi

Authors
  1. Koji Kamiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroyoshi Yamauchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mamitaro Ohtsuki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mamitaro Ohtsuki.

Additional information

Disclosure

Financial support: none. Conflicts of interest: none.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kamiya, K., Yamauchi, H. & Ohtsuki, M. Treatment of psoriasis vulgaris with guselkumab in a patient with non-small cell lung cancer. Eur J Dermatol 30, 609–611 (2020). https://doi.org/10.1684/ejd.2020.3860

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1684/ejd.2020.3860

Search

Navigation